Designed with Purposeful Add‑Back Therapy
Myfembree is purposefully designed to relieve bleeding from uterine fibroids while mitigating side effects like bone loss, associated with relugolix alone1-4
INDICATIONS
Myfembree is indicated in premenopausal women for the management of:
- Heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
- Moderate to severe pain associated with endometriosis
Limitations of Use: Use of Myfembree should be limited to 24 months due to the risk of continued bone loss which may not be reversible.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS
- Estrogen and progestin combination products, including Myfembree, increase the risk of thrombotic or thromboembolic disorders including pulmonary embolism, deep vein thrombosis, stroke and myocardial infarction, especially in women at increased risk for these events.
- Myfembree is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and those at increased risk for these events, including women >35 years of age who smoke or with uncontrolled hypertension.
CONTRAINDICATIONS
Myfembree is contraindicated in women with: high risk of arterial, venous thrombotic, or thromboembolic disorder; pregnancy; known osteoporosis; current or history of breast- or other hormone-sensitive cancers; known hepatic impairment or disease; undiagnosed abnormal uterine bleeding; known hypersensitivity to components of Myfembree.
WARNINGS AND PRECAUTIONS
Thromboembolic Disorders: Discontinue immediately if an arterial or venous thrombotic, cardiovascular, or cerebrovascular event occurs or is suspected; or if there is sudden unexplained partial or complete loss of vision, proptosis, diplopia, papilledema or retinal vascular lesions and evaluate for retinal vein thrombosis. Discontinue ≥4 to 6 weeks before surgery associated with an increased risk of thromboembolism or during prolonged immobilization.
Bone Loss: Myfembree may decrease bone mineral density (BMD) in some patients, which may be greater with longer use and may not be completely reversible. Consider the benefits and risks in patients with a history of low trauma fracture or risk factors for osteoporosis or bone loss. Baseline dual-energy X-ray absorptiometry (DXA) is recommended in all women. During treatment, DXA is recommended periodically for heavy menstrual bleeding due to uterine fibroids and annually for moderate to severe endometriosis pain.
Hormone-Sensitive Malignancies: Discontinue Myfembree if a hormone-sensitive malignancy is diagnosed. Breast exams and mammography are recommended. Use of estrogen alone or estrogen plus progestin has resulted in abnormal mammograms requiring further evaluation.
Suicidal Ideation and Mood Disorders (Including Depression): Evaluate patients with a history of suicidal ideation, depression, and mood disorders before starting treatment. Monitor for these symptoms including shortly after initiating treatment. Advise patients to seek medical care for new or worsening depression, anxiety, other mood changes, or suicidal ideation and behavior. Gonadotropin-releasing hormone receptor antagonists, including Myfembree, have been associated with mood disorders (including depression) and suicidal ideation.
Hepatic Impairment and Transaminase Elevations: Due to poor metabolism of steroid hormones, instruct these patients to promptly seek medical care for symptoms/signs of liver injury, e.g., jaundice or right upper abdominal pain. Acute liver test abnormalities may require discontinuing Myfembree until tests return to normal and Myfembree causation is excluded.
Gallbladder Disease or History of Cholestatic Jaundice: Discontinue Myfembree if signs/symptoms of gallbladder disease or jaundice occur. Studies among estrogen users suggest a small increased relative risk of developing gallbladder disease.
Elevated Blood Pressure: In women with well-controlled hypertension, monitor blood pressure and stop Myfembree if it rises significantly.
Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy: Advise women to use non-hormonal contraception during and for one week after discontinuing Myfembree. Avoid use with hormonal contraceptives. Myfembree may delay recognition of pregnancy because it alters menstrual bleeding. Test for pregnancy if suspected and discontinue Myfembree if confirmed.
Risk of Early Pregnancy Loss: Myfembree can cause early pregnancy loss. Exclude pregnancy before initiating and advise women to use non-hormonal contraception.
Uterine Fibroid Prolapse or Expulsion: Advise women with known or suspected submucosal uterine fibroids about the risk of uterine fibroid prolapse or expulsion and instruct them to contact their physician if severe bleeding/cramping occurs.
Alopecia: Alopecia, hair loss, and hair thinning were reported in phase 3 trials in women with heavy menstrual bleeding associated with uterine fibroids with Myfembree. Whether hair loss is reversible is unknown.
Effects on Carbohydrate and Lipid Metabolism: More frequent monitoring in women with prediabetes and diabetes may be necessary. Myfembree may decrease glucose tolerance and increase blood glucose concentrations. Monitor lipid levels and consider discontinuing if hypercholesterolemia or hypertriglyceridemia worsens. In women with pre-existing hypertriglyceridemia, estrogen therapy may increase triglycerides levels leading to pancreatitis. Myfembree is associated with increases in total cholesterol and LDL-C.
Effect on Other Laboratory Results: Patients with hypothyroidism and hypoadrenalism may require higher doses of thyroid hormone or cortisol replacement therapy. Combined estrogen and progestin may raise serum concentrations of binding proteins, which may reduce free thyroid or corticosteroid hormone levels. Estrogen and progestin may also affect the levels of sex hormone-binding globulin and coagulation factors.
Hypersensitivity Reactions: Immediately discontinue Myfembree if a hypersensitivity reaction occurs.
ADVERSE REACTIONS: Most common adverse reactions (incidence ≥3% and greater than placebo) were:
- Heavy menstrual bleeding associated with uterine fibroids: vasomotor symptoms, abnormal uterine bleeding, alopecia, and decreased libido.
- Moderate to severe pain associated with endometriosis: headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, and dizziness.
These are not all the possible side effects.
LACTATION: Advise women not to breastfeed while taking Myfembree.
Please see Important Safety Information throughout and full Prescribing Information, including BOXED WARNING
References
- Myfembree [Prescribing Information]. Sumitomo Pharma America, Inc. July 2024.
- Al-Hendy A, Lukes AS, Poindexter AN III, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630-642.
- Arjona Ferreira JC, Migoya E. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. FS Rep. 2022;4(2S):73-82.
- Friedman AJ, Lobel SM, Rein MS, et al. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen
threshold hypothesis. Am J Obstet Gynecol. 1990;163(4):1114-1119. - Data on file. Sumitomo Pharma America, Inc.
INDICATIONS
Myfembree is indicated in premenopausal women for the management of:
- Heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
- Moderate to severe pain associated with endometriosis
Limitations of Use: Use of Myfembree should be limited to 24 months due to the risk of continued bone loss which may not be reversible.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS
- Estrogen and progestin combination products, including Myfembree, increase the risk of thrombotic or thromboembolic disorders including pulmonary embolism, deep vein thrombosis, stroke and myocardial infarction, especially in women at increased risk for these events.
- Myfembree is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and those at increased risk for these events, including women >35 years of age who smoke or with uncontrolled hypertension.
CONTRAINDICATIONS
Myfembree is contraindicated in women with: high risk of arterial, venous thrombotic, or thromboembolic disorder; pregnancy; known osteoporosis; current or history of breast- or other hormone-sensitive cancers; known hepatic impairment or disease; undiagnosed abnormal uterine bleeding; known hypersensitivity to components of Myfembree.
WARNINGS AND PRECAUTIONS
Thromboembolic Disorders: Discontinue immediately if an arterial or venous thrombotic, cardiovascular, or cerebrovascular event occurs or is suspected; or if there is sudden unexplained partial or complete loss of vision, proptosis, diplopia, papilledema or retinal vascular lesions and evaluate for retinal vein thrombosis. Discontinue ≥4 to 6 weeks before surgery associated with an increased risk of thromboembolism or during prolonged immobilization.
Bone Loss: Myfembree may decrease bone mineral density (BMD) in some patients, which may be greater with longer use and may not be completely reversible. Consider the benefits and risks in patients with a history of low trauma fracture or risk factors for osteoporosis or bone loss. Baseline dual-energy X-ray absorptiometry (DXA) is recommended in all women. During treatment, DXA is recommended periodically for heavy menstrual bleeding due to uterine fibroids and annually for moderate to severe endometriosis pain.
Hormone-Sensitive Malignancies: Discontinue Myfembree if a hormone-sensitive malignancy is diagnosed. Breast exams and mammography are recommended. Use of estrogen alone or estrogen plus progestin has resulted in abnormal mammograms requiring further evaluation.
Suicidal Ideation and Mood Disorders (Including Depression): Evaluate patients with a history of suicidal ideation, depression, and mood disorders before starting treatment. Monitor for these symptoms including shortly after initiating treatment. Advise patients to seek medical care for new or worsening depression, anxiety, other mood changes, or suicidal ideation and behavior. Gonadotropin-releasing hormone receptor antagonists, including Myfembree, have been associated with mood disorders (including depression) and suicidal ideation.
Hepatic Impairment and Transaminase Elevations: Due to poor metabolism of steroid hormones, instruct these patients to promptly seek medical care for symptoms/signs of liver injury, e.g., jaundice or right upper abdominal pain. Acute liver test abnormalities may require discontinuing Myfembree until tests return to normal and Myfembree causation is excluded.
Gallbladder Disease or History of Cholestatic Jaundice: Discontinue Myfembree if signs/symptoms of gallbladder disease or jaundice occur. Studies among estrogen users suggest a small increased relative risk of developing gallbladder disease.
Elevated Blood Pressure: In women with well-controlled hypertension, monitor blood pressure and stop Myfembree if it rises significantly.
Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy: Advise women to use non-hormonal contraception during and for one week after discontinuing Myfembree. Avoid use with hormonal contraceptives. Myfembree may delay recognition of pregnancy because it alters menstrual bleeding. Test for pregnancy if suspected and discontinue Myfembree if confirmed.
Risk of Early Pregnancy Loss: Myfembree can cause early pregnancy loss. Exclude pregnancy before initiating and advise women to use non-hormonal contraception.
Uterine Fibroid Prolapse or Expulsion: Advise women with known or suspected submucosal uterine fibroids about the risk of uterine fibroid prolapse or expulsion and instruct them to contact their physician if severe bleeding/cramping occurs.
Alopecia: Alopecia, hair loss, and hair thinning were reported in phase 3 trials in women with heavy menstrual bleeding associated with uterine fibroids with Myfembree. Whether hair loss is reversible is unknown.
Effects on Carbohydrate and Lipid Metabolism: More frequent monitoring in women with prediabetes and diabetes may be necessary. Myfembree may decrease glucose tolerance and increase blood glucose concentrations. Monitor lipid levels and consider discontinuing if hypercholesterolemia or hypertriglyceridemia worsens. In women with pre-existing hypertriglyceridemia, estrogen therapy may increase triglycerides levels leading to pancreatitis. Myfembree is associated with increases in total cholesterol and LDL-C.
Effect on Other Laboratory Results: Patients with hypothyroidism and hypoadrenalism may require higher doses of thyroid hormone or cortisol replacement therapy. Combined estrogen and progestin may raise serum concentrations of binding proteins, which may reduce free thyroid or corticosteroid hormone levels. Estrogen and progestin may also affect the levels of sex hormone-binding globulin and coagulation factors.
Hypersensitivity Reactions: Immediately discontinue Myfembree if a hypersensitivity reaction occurs.
ADVERSE REACTIONS: Most common adverse reactions (incidence ≥3% and greater than placebo) were:
- Heavy menstrual bleeding associated with uterine fibroids: vasomotor symptoms, abnormal uterine bleeding, alopecia, and decreased libido.
- Moderate to severe pain associated with endometriosis: headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, and dizziness.
These are not all the possible side effects.
LACTATION: Advise women not to breastfeed while taking Myfembree.
Please see Important Safety Information throughout and full Prescribing Information, including BOXED WARNING